Listed

Innodata Inc: Form 10-Q for the period ended Jun 30, 2024

Filed with the SEC on Aug 9, 2024 and accepted by EDGAR at Aug 8, 2024, 18:00 ET.

Share

Management's discussion and analysis

As filed, 69,886 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL

CONDITION AND RESULTS OF OPERATIONS

Cautionary Note Regarding Forward-Looking Statements

Disclosures in this Quarterly Report on Form 10-Q (this “Report”) contain certain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These forward-looking statements include, without limitation, statements concerning our operations, economic performance, financial condition, developmental program expansion and position in the generative AI services market. Words such as “project,” “believe,” “expect,” “can,” “continue,” “could,” “intend,” “may,” “should,” “will,” “anticipate,” “indicate,” “predict,” “likely,” “estimate,” “plan,” “potential,” “possible,” or the negatives thereof, and other similar expressions generally identify forward-looking statements.

These forward-looking statements are based on management’s current expectations, assumptions and estimates and are subject to a number of risks and uncertainties, including, without limitation, impacts resulting from ongoing geopolitical conflicts, including between Russia and the Ukraine, Hamas’ attack against Israel and the ensuing conflict and increased hostilities between Iran and Israel; investments in large language models; that contracts may be terminated by customers; projected or committed volumes of work may not materialize; pipeline opportunities and customer discussions which may not materialize into work or expected volumes of work; the likelihood of continued development of the markets, particularly new and emerging markets, that our services support; the ability and willingness of our customers and prospective customers to execute business plans that give rise to requirements for our services; continuing reliance on project-based work in the Digital Data Solutions (DDS) segment and the primarily at-will nature of such contracts and the ability of these customers to reduce, delay or cancel projects; potential inability to replace projects that are completed, canceled or reduced; continuing DDS segment revenue concentration in a limited number of customers; our dependency on content providers in our Agility segment; the Company’s ability to achieve revenue and growth targets; difficulty in integrating and deriving synergies from acquisitions, joint ventures and strategic investments; potential undiscovered liabilities of companies and businesses that we may acquire; potential impairment of the carrying value of goodwill and other acquired intangible assets of companies and businesses that we acquire; a continued downturn in or depressed market conditions; changes in external market factors; the potential effects of U.S. monetary policy, including the interest rate policies of the Federal Reserve; changes in our business or growth strategy; the emergence of new, or growth in existing competitors; various other competitive and technological factors; our use of and reliance on information technology systems, including potential security breaches, cyber-attacks, privacy breaches or data breaches that result in the unauthorized disclosure of consumer, customer, employee or Company information, or service interruptions; and other risks and uncertainties indicated from time to time on our filings with the Securities and Exchange Commission.

Our actual results could differ materially from the results referred to in forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the risks discussed in Part I, Item 1A. “Risk Factors,” Part II, Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and other parts of our Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 4, 2024 and in our other filings that we may make with the Securities and Exchange Commission.

In light of these risks and uncertainties, there can be no assurance that the results referred to in the forward-looking statements will occur, and you should not place undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof.

We undertake no obligation to update or review any guidance or other forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required by the U.S. federal securities laws.

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to help the reader understand the results of operations and financial condition of Innodata Inc. and its subsidiaries and should be read in conjunction with our unaudited condensed consolidated financial statements and the accompanying notes to condensed consolidated financial statements contained in Part I, Item 1. “Financial Statements” of this Report.

Business Overview

Innodata Inc. (Nasdaq: INOD) (including its subsidiaries, the “Company,” “Innodata,” “we,” “us” or “our”) is a leading data engineering company. Our mission is to help the world’s most prestigious companies deliver the promise of ethical, high-performing artificial intelligence (“AI”), which we believe will contribute to a safer and more prosperous world.

Innodata was founded on a simple idea: engineer the highest quality data so organizations across broad industry segments could make smarter decisions. Today, we believe we are delivering the highest quality data for some of the world’s most innovative technology companies to use to train the AI models of the future.

AI holds the promise that computers can perceive and understand the world, enabling products and services that would have been previously unimaginable and impossible with traditional coding. AI learns from data, and the highest-performing AI will have learned from the highest-quality data. We believe that we can contribute meaningfully by harnessing our capabilities, honed over 30+ years, in collecting and annotating data at scale with consistency and high accuracy.

We are also helping companies deploy and integrate AI into their operations and products and providing innovative AI-enabled industry platforms, helping ensure that our customers’ businesses are prepared for a world in which machines augment human activity in ways previously unimaginable.

We developed our capabilities and honed our approaches progressively over the last 30+ years creating high-quality data for many of the world’s most demanding information companies. Approximately eight years ago, we formed Innodata Labs, a research and development center, to research, develop and apply machine learning and emerging AI to our large-scale, human-intensive data operations. In 2019, we began packaging the capabilities that emerged from our R&D efforts in order to align with several fast-growing new markets and help companies use AI/ML to drive performance benefits and business insights.

Our historical core competency in high-quality data, combined with these R&D efforts in applied AI, created the foundation for the evolution of our offerings, which include AI Data Preparation, AI Model Deployment and Integration, and AI-Enabled Industry Platforms.

AI Data Preparation

For several of the world’s large technology companies, we support their efforts at building generative AI foundation models. For these companies, we provide or are poised to provide a range of scaled data solutions and services. Our scaled data solutions include providing instruction data sets for fine-tuning large language models (LLMs) to understand prompts, to accept instruction, to converse, to apparently reason, and to perform the myriad of incredible feats that many of us have now experienced. We also provide reinforcement learning and reward modeling, services which are critical to provide the guardrails against toxic, bias and harmful responses, and model evaluation services.

For social media companies, robotics companies, financial services companies, and many others, we collect or create training data, annotate training data, and train AI algorithms for working with images, text, video, audio, code and sensor data.

We utilize a variety of leading third-party tools, proprietary tools and customer tools. For text annotation, we use our proprietary data annotation platform that incorporates AI to reduce costs while improving consistency and quality of output. Our proprietary data annotation platform features auto-tagging capabilities that apply to both classical and generative AI tasks. The platform encapsulates many of the innovations we conceived of in the course of its 30+ year history of creating high-quality data.

In addition, because collecting real-world data is often impracticable (due to data privacy regulations or the rarity of cohorts and outliers), we create high-quality synthetic data that maintains all of the statistical properties of real-world data, using a combination of domain specialists and machine technologies that leverage LLMs.

AI Model Deployment and Integration

We help businesses leverage the latest AI technologies to achieve their goals. We develop custom AI models (where we select the appropriate algorithms, tune hyperparameters, train and validate the models, and update the models as required). We also help businesses fine-tune their own custom versions of our proprietary models and third-party foundation models to address domain-specific and customer-specific use cases.

For our customers that provide products and solutions that require intensive text data processing and analytics, in addition to deploying and integrating AI models, we often provide a range of data engineering support services including data transformation, data curation, data hygiene, data consolidation, data extraction, data compliance, and master data management.

Our customers span a diverse range of industries and a wide range of AI use cases, benefiting from the short time-to-value and high economic returns of our AI solutions and platforms.

AI-Enabled Industry Platforms

Our AI-enabled industry platforms address specific, niche market requirements we believe we can innovate with AI/ML technologies. We deploy these industry platforms as software-as-a-service (SaaS) and as managed services. These platforms benefit from our technology infrastructure, our industry-specific knowledge, our strong customer relationships and experience merging technology with the business processes of our customers. To date, we have built an industry platform for medical records data extraction and transformation (which we brand as “Synodex®”) and an industry platform for public relations (which we brand as “Agility PR Solutions”). We are in the development with an additional AI-enabled industry platform to serve financial services institutions.

Our Synodex industry platform transforms medical records into useable digital data organized in accordance with our proprietary data models or customer data models.

Our Agility industry platform provides marketing communications and public relations professionals with the ability to target and distribute content to journalists and social media influencers world-wide and to monitor and analyze global news (print, web, radio and TV) and social media.

Our operations are presently classified and reported in three reporting segments: Digital Data Solutions (DDS), Synodex and Agility.

Prevailing Economic Conditions and Seasonality

Prevailing Economic Conditions

With the current level of demand for our services, we believe we have existing cash and cash equivalents that provide sufficient sources of liquidity to satisfy our financial needs for at least the next 12 months from the date of the filing of this Report (refer to Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources” for additional information). In the event we experience a significant or prolonged reduction in revenues, the likelihood of which is uncertain, we would seek to manage our liquidity by utilizing the Revolving Credit Facility, reducing capital expenditures, deferring investment activities, and reducing operating costs.

Seasonality

Our quarterly operating results are subject to certain fluctuations. We experience fluctuations in our revenue and earnings as we replace and begin new projects, which may have some normal start-up delays, or we may be unable to replace a project entirely. These and other factors may contribute to fluctuations in our operating results from quarter to quarter. In addition, as some of our Asian facilities are closed during holidays in the fourth quarter, we typically incur higher wages, due to overtime, that reduce our margins.

Our Synodex subsidiary experiences seasonal fluctuations in revenues. Typically, revenue is lowest in the third quarter of the calendar year and highest in the fourth quarter of the calendar year. The seasonality is directly linked to the number of life insurance applications received by the insurance companies.

For further information, refer to the risk factor titled “Quarterly fluctuations in our revenues and results of operations could make financial forecasting difficult and could negatively affect our stock price.” in Part I, Item 1A. “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2023.

Non-GAAP Financial Measures

In addition to the financial information prepared in conformity with U.S. GAAP (“GAAP”), we provide certain non-GAAP financial information. We believe that these non-GAAP financial measures assist investors in making comparisons of period-to-period operating results. In some respects, management believes non-GAAP financial measures are more indicative of our ongoing core operating performance than their GAAP equivalents by making adjustments that management believes are reflective of the ongoing performance of the business.

We believe that the presentation of this non-GAAP financial information provides investors with greater transparency by providing investors a more complete understanding of our financial performance, competitive position, and prospects for the future, particularly by providing the same information that management and our Board of Directors use to evaluate our performance and manage the business. However, the non-GAAP financial measures presented in this Quarterly Report on Form 10-Q have certain limitations in that they do not reflect all of the costs associated with the operations of our business as determined in accordance with GAAP. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures that we present may differ from similar non-GAAP financial measures used by other companies.

Adjusted Gross Profit and Adjusted Gross Margin

We define Adjusted Gross Profit as revenues less direct operating costs attributable to Innodata Inc. and its subsidiaries in accordance with U.S. GAAP, plus depreciation and amortization of intangible assets, stock-based compensation, non-recurring severance and other one-time costs.

We define Adjusted Gross Margin by dividing Adjusted Gross Profit over total U.S. GAAP revenues.

We use Adjusted Gross Profit and Adjusted Gross Margin to evaluate results of operations and trends between fiscal periods and believe that these measures are important components of our internal performance measurement process.

The following table contains a reconciliation of Gross Profit and Gross Margin in accordance with the U.S. GAAP attributable to Innodata Inc. and its subsidiaries to Adjusted Gross Profit and Adjusted Gross Margin for the three and six-month periods ended June 30, 2024 and 2023 (in thousands).

​ ​ Consolidated ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, 2024 ​ ​ ​ ​ ​ ​ 2023 ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2024 ​ ​ ​ ​ ​ ​ ​ 2023 ​ ​ ​ ​
Gross Profit attributable to Innodata Inc. and Subsidiaries ​ $9,351 $6,940 ​ $18,986 ​ $12,905 ​
Depreciation and amortization ​ 1,394 ​ 1,124 ​ ​ 2,634 ​ ​ 2,188 ​
Severance** ​ - ​ - ​ ​ - ​ ​ 327 ​
Stock-based compensation ​ 73 ​ 62 ​ ​ 157 ​ ​ 126 ​
Adjusted Gross Profit ​ $10,818 $8,126 ​ $21,777 ​ $15,546 ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Gross Margin ​ 29% ​ 35% ​ 32% ​ 34%
Adjusted Gross Margin ​ ​ 33% ​ 41% ​ 37% ​ 40%
​ ​ DDS Segment ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, 2024 ​ ​ ​ ​ ​ ​ 2023 ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2024 ​ ​ ​ ​ ​ ​ ​ 2023 ​ ​ ​ ​
Gross Profit attributable to DDS Segment ​ $6,079 $4,398 ​ $12,637 ​ $8,557 ​
Depreciation and amortization ​ 455 ​ 230 ​ ​ 793 ​ ​ 429 ​
Severance** ​ - ​ - ​ ​ - ​ ​ 28 ​
Stock-based compensation ​ 64 ​ 60 ​ ​ 138 ​ ​ 112 ​
Adjusted Gross Profit ​ $6,598 $4,688 ​ $13,568 ​ $9,126 ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Gross Margin ​ 24% ​ 33% ​ 28% ​ 33%
Adjusted Gross Margin ​ ​ 26% ​ 36% ​ 30% ​ 35%
​ ​ Synodex Segment ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, 2024 ​ ​ ​ ​ ​ ​ 2023 ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2024 ​ ​ ​ ​ ​ ​ ​ 2023 ​ ​ ​ ​
Gross Profit attributable to Synodex Segment ​ $456 $295 ​ $855 ​ $498 ​
Depreciation and amortization ​ 157 ​ 162 ​ ​ 294 ​ ​ 324 ​
Severance** ​ - ​ - ​ ​ - ​ ​ - ​
Stock-based compensation ​ - ​ - ​ ​ - ​ ​ - ​
Adjusted Gross Profit ​ $613 $457 ​ $1,149 ​ $822 ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Gross Margin ​ 23% ​ 14% ​ 22% ​ 13%
Adjusted Gross Margin ​ ​ 31% ​ 22% ​ 30% ​ 21%
​ ​ Agility Segment ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, 2024 ​ ​ ​ ​ ​ ​ 2023 ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2024 ​ ​ ​ ​ ​ ​ ​ 2023 ​ ​ ​ ​
Gross Profit attributable to Agility Segment ​ $2,816 $2,247 ​ $5,494 ​ $3,850 ​
Depreciation and amortization ​ 782 ​ 732 ​ ​ 1,547 ​ ​ 1,435 ​
Severance** ​ - ​ - ​ ​ - ​ ​ 299 ​
Stock-based compensation ​ 9 ​ 2 ​ ​ 19 ​ ​ 14 ​
Adjusted Gross Profit ​ $3,607 $2,981 ​ $7,060 ​ $5,598 ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Gross Margin ​ 55% ​ 52% ​ 54% ​ 45%
Adjusted Gross Margin ​ ​ 70% ​ 68% ​ 70% ​ 65%

** Represents non-recurring severance incurred for a reduction in headcount in connection with the re-alignment of the Company’s cost structure.

Adjusted EBITDA

We define Adjusted EBITDA as net income (loss) attributable to Innodata Inc. and its subsidiaries in accordance with U.S. GAAP before interest expense, income taxes, depreciation and amortization of intangible assets (which derives EBITDA), plus additional adjustments for loss on impairment of intangible assets and goodwill, stock-based compensation, income (loss) attributable to non-controlling interests, non-recurring severance, and other one-time costs. We use Adjusted EBITDA to evaluate core results of operations and trends between fiscal periods and believe that these measures are important components of our internal performance measurement process.

The following table contains a reconciliation of U.S. GAAP net income (loss) attributable to Innodata Inc. and its subsidiaries to Adjusted EBITDA (loss) for the three and six-month periods ended June 30, 2024 and 2023 (in thousands).

​ ​ Consolidated ​ ​ ​ Three Months Ended June 30, 2024 ​ ​ ​ 2023 ​ ​ ​ ​ Six Months Ended June 30, 2024 ​ ​ ​ 2023
Net income (loss) attributable to Innodata Inc. and Subsidiaries ​ $(14) ​ $(815) ​ $975 ​ $(2,931)
Provision for income taxes ​ ​ 285 ​ ​ 188 ​ 709 ​ 406
Interest expense ​ ​ 101 ​ ​ 40 ​ 169 ​ 132
Depreciation and amortization ​ ​ 1,418 ​ ​ 1,151 ​ 2,684 ​ 2,242
Severance** ​ ​ - ​ ​ - ​ ​ - ​ ​ 580
Stock-based compensation ​ ​ 992 ​ ​ 1,019 ​ 2,026 ​ 1,981
Non-controlling interests ​ ​ 5 ​ ​ - ​ 6 ​ 3
Adjusted EBITDA - Consolidated ​ $2,787 ​ $1,583 ​ $6,569 ​ $2,413
​ ​ DDS Segment ​ ​ ​ ​ Three Months Ended June 30, 2024 ​ ​ ​ 2023 ​ ​ ​ ​ Six Months Ended June 30, 2024 ​ ​ ​ 2023
Net loss attributable to DDS Segment ​ $(460) ​ $(554) ​ $(34) ​ $(1,195)
Provision for income taxes ​ ​ 283 ​ ​ 186 ​ ​ 704 ​ ​ 400
Interest expense ​ ​ 100 ​ ​ 38 ​ 167 ​ 130
Depreciation and amortization ​ ​ 479 ​ ​ 257 ​ ​ 843 ​ ​ 483
Severance** ​ ​ - ​ ​ - ​ ​ - ​ ​ 33
Stock-based compensation ​ ​ 868 ​ ​ 865 ​ ​ 1,763 ​ ​ 1,670
Non-controlling interests ​ ​ 5 ​ ​ - ​ ​ 6 ​ ​ 3
Adjusted EBITDA - DDS Segment ​ $1,275 ​ $792 ​ $3,449 ​ $1,524
​ ​ Synodex Segment ​ ​ ​ ​ Three Months Ended June 30, 2024 ​ ​ ​ 2023 ​ ​ ​ Six Months Ended June 30, 2024 ​ ​ ​ 2023
Net income attributable to Synodex Segment ​ $316 ​ $121 ​ $592 ​ $135
Depreciation and amortization ​ ​ 157 ​ 162 ​ ​ 294 ​ ​ 324
Severance** ​ ​ - ​ ​ - ​ ​ - ​ ​ 6
Stock-based compensation ​ 49 ​ 59 ​ 98 ​ 117
Adjusted EBITDA - Synodex Segment ​ $522 ​ $342 ​ $984 ​ $582
​ ​ Agility Segment ​ ​ ​ ​ Three Months Ended June 30, 2024 ​ ​ ​ 2023 ​ ​ ​ ​ Six Months Ended June 30, 2024 ​ ​ ​ 2023
Net income (loss) attributable to Agility Segment ​ $130 ​ $(382) ​ $417 ​ $(1,871)
Provision for income taxes ​ ​ 2 ​ ​ 2 ​ 5 ​ 6
Interest expense ​ ​ 1 ​ ​ 2 ​ 2 ​ 2
Depreciation and amortization ​ ​ 782 ​ ​ 732 ​ 1,547 ​ 1,435
Severance** ​ ​ - ​ ​ - ​ ​ - ​ ​ 541
Stock-based compensation ​ ​ 75 ​ ​ 95 ​ 165 ​ 194
Adjusted EBITDA - Agility Segment ​ $990 ​ $449 ​ $2,136 ​ $307

** Represents non-recurring severance incurred for a reduction in headcount in connection with the re-alignment of the Company’s cost structure.

Results of Operations

The amounts in the MD&A below have been rounded. All percentages have been calculated using rounded amounts.

Three Months Ended June 30, 2024 and 2023

Revenues

Total revenues were $32.6 million and $19.7 million for the three months ended June 30, 2024 and 2023, respectively, an increase of $12.9 million or approximately 66%.

Revenues from the DDS segment were $25.4 million and $13.2 million for the three months ended June 30, 2024 and 2023, respectively, an increase of $12.2 million or approximately 93%. The increase was primarily attributable to higher volume from an existing customer.

Revenues from the Synodex segment were $2.0 million and $2.1 million for the three months ended June 30, 2024 and 2023, respectively, a decrease of $0.1 million or 6%. The decrease was primarily attributable to lower volume from existing customers.

Revenues from the Agility segment were $5.2 million and $4.4 million for the three months ended June 30, 2024 and 2023, respectively, an increase of $0.8 million or approximately 18%. The increase was principally attributable to higher volumes from subscriptions to our Agility AI-enabled industry platform.

One customer in the DDS segment generated approximately 38% of the Company’s total revenues for the three months ended June 30, 2024. Another customer in the DDS segment generated approximately 10% of the Company’s total revenues for the three months ended June 30, 2023. No other customer accounted for 10% or more of total revenues during these periods. Further, for the three months ended June 30, 2024 and 2023, revenues from non-U.S. customers accounted for 27% and 44% respectively, of the Company’s total revenues.

Direct Operating Costs

Direct operating costs consist of direct and indirect labor costs, occupancy costs, data center hosting fees, cloud services, content acquisition costs, depreciation and amortization, travel, telecommunications, computer services and supplies, realized (gain) loss on forward contracts, foreign currency revaluation (gain) loss, and other direct expenses that are incurred in providing services to our customers.

Direct operating costs were $23.2 million and $12.7 million for the three months ended June 30, 2024 and 2023, respectively, an increase of $10.5 million or 83%. The cost increase was primarily due to increased headcount to support higher volumes from an existing customer. The increase in direct operating costs includes $6.7 million from direct and indirect labor related costs primarily on account of new hires and higher incentives; higher recruitment fees of $3.6 million; higher depreciation and amortization of capitalized developed software of $0.3 million; higher subscription costs of $0.2 million; higher content costs of $0.2 million; offset in part by a favorable impact of foreign exchange rate fluctuations of $0.5 million. Direct operating costs as a percentage of total revenues were 71% and 64% for the three months ended June 30, 2024 and 2023, respectively. The increase in direct operating cost as a percentage of total revenues was primarily due to higher revenues in the DDS and Agility segments and lower direct operating costs in the Synodex segment; offset in part by higher direct operating costs in the DDS and Agility segments.

Direct operating costs for the DDS segment were $19.3 million and $8.8 million for the three months ended June 30, 2024 and 2023, respectively, an increase of $10.5 million or 119%. The cost increase was primarily due to increased headcount to support higher volumes from an existing customer. The increase in direct operating costs includes $7.2 million from direct and indirect labor related costs primarily on account of new hires and higher incentives; higher recruitment fees of $3.6 million; higher depreciation and amortization of capitalized developed software of $0.2 million; higher subscription costs of $0.1 million; offset in part by a favorable impact of foreign exchange rate fluctuations of $0.5 million and a decrease in other direct operating costs of $0.1 million. Direct operating costs for the DDS segment as a percentage of DDS segment revenues were 76% and 67% for the three months ended June 30, 2024 and 2023, respectively. The increase in direct operating costs of the DDS segment as a percentage of DDS segment revenues was primarily attributable to higher revenues, offset in part by higher direct operating costs.

Direct operating costs for the Synodex segment were $1.5 million and $1.8 million for the three months ended June 30, 2024 and 2023, respectively, a decrease of $0.3 million or 17%. The decrease in direct operating costs was primarily due to the effect of the cost optimization initiatives completed in 2023 which resulted in cost efficiencies for the Synodex segment. The reduction was primarily due to lower direct labor costs of $0.3 million. Direct operating costs for the Synodex segment as a percentage of Synodex segment revenues were 75% and 86% for the three months ended June 30, 2024 and 2023, respectively. The decrease in direct operating costs of the Synodex segment as a percentage of Synodex segment revenues was due to a decrease in direct operating costs, offset in part by lower revenues.

Direct operating costs for the Agility segment were $2.3 million and $2.1 million for the three months ended June 30, 2024 and 2023, respectively, an increase of $0.2 million or 10%. The increase in direct operating costs was a result of lower direct labor costs of $0.2 million; offset by higher content costs of $0.2 million; higher depreciation and amortization of capitalized developed software of $0.1 million and an increase in other direct operating costs of $0.1 million. Direct operating costs for the Agility segment as a percentage of Agility segment revenues were 44% and 48% for the three months ended June 30, 2024 and 2023, respectively. The decrease in direct operating costs of the Agility segment as a percentage of Agility segment revenues was due to higher revenues, and lower direct operating costs.

Gross Profit and Gross Margin

Gross profit is derived by revenues less direct operating costs, while the Gross margin percentage is derived by dividing gross profit over revenues.

Gross profit was $9.3 million and $6.9 million for the three months ended June 30, 2024 and 2023, respectively. The $2.4 million increase in gross profit was primarily due to higher revenues in the DDS and Agility segments and lower direct operating costs for the Synodex segments, offset in part by higher direct operating costs in the DDS and Agility segments. Gross margin was 29% and 35% for the three months ended June 30, 2024 and 2023, respectively. The decrease in gross margin was primarily due to higher revenues in the DDS and Agility segments and lower direct operating costs for the Synodex segment; offset in part by higher direct operating costs in the DDS and Agility segments.

Gross profit for the DDS segment was $6.1 million and $4.4 million for the three months ended June 30, 2024 and 2023, respectively. The $1.7 million increase in gross profit for the DDS segment was primarily due to higher revenues, offset in part by higher direct operating costs. Gross margin for the DDS segment was 24% and 33% for the three months ended June 30, 2024 and 2023, respectively. The decrease in gross margin for the DDS segment as a percentage of revenues was primarily due to higher revenues, offset in part by higher direct operating costs.

Gross profit for the Synodex segment was $0.5 million and $0.3 million for the three months ended June 30, 2024 and 2023, respectively. The $0.2 million increase in gross profit for the Synodex segment was primarily due to lower direct operating costs, offset in part by lower revenues. Gross margin for the Synodex segment was 23% and 14% for the three months ended June 30, 2024 and 2023, respectively. The increase in gross margin for the Synodex segment as a percentage of revenues was primarily due to lower direct operating costs, offset in part by lower revenues.

Gross profit for the Agility segment was $2.8 million and $2.2 million for the three months ended June 30, 2024 and 2023, respectively. The $0.6 million increase in gross profit for the Agility segment was primarily due to higher revenues, offset in part by higher direct operating costs. Gross margin for the Agility segment was 55% and 52% for the three months ended June 30, 2024 and 2023, respectively. The increase in gross margin for the Agility segment as a percentage of revenues was primarily due to higher revenues, offset in part by higher direct operating costs.

Selling and Administrative Expenses

Selling and administrative expenses consist of payroll and related costs including commissions, bonuses, and stock-based compensation; marketing, advertising, trade conferences and related expenses; new services research and related software development expenses, software subscriptions, professional and consultant fees, provision for credit losses and other administrative overhead expenses.

Selling and administrative expenses were $9.0 million and $7.6 million for the three months ended June 30, 2024 and 2023, respectively, an increase of $1.4 million or 18%. The increase in selling and administrative expenses was primarily due to higher expenses associated with the increase in revenues. The increase in selling and administrative expenses includes higher selling and administrative labor and related expenses of $1.0 million, primarily on account of new hires, salary increases, incentives and bonuses awarded; higher professional fees of $0.3 million; and an increase in other selling and administrative expenses of $0.2 million; offset in part by lower provision for credit losses of $0.1 million. Selling and administrative expenses as a percentage of total revenues were 28% and 39% for the three months ended June 30, 2024 and 2023, respectively. The decrease in selling and administrative expenses as a percentage of total revenues was primarily attributable to higher revenues in the DDS and Agility segments and lower selling and administrative expenses in the Synodex segment, offset in part by higher selling and administrative expenses in the DDS and Agility segments.

Selling and administrative expenses for the DDS segment were $6.2 million and $4.8 million for the three months ended June 30, 2024 and 2023, respectively, an increase of $1.4 million or 29%. The increase in selling and administrative expenses was primarily due to higher expenses associated with the increase in revenues. The increase in selling and administrative expenses includes higher selling and administrative labor and related expenses of $1.0 million, primarily on account of new hires, salary increases, incentives and bonuses awarded; higher professional fees of $0.3 million and an increase in other selling and administrative expenses of $0.2 million; offset in part by lower provisions for credit losses of $0.1 million. Selling and administrative expenses for the DDS segment as a percentage of DDS segment revenues were 24% and 36% for the three months ended June 30, 2024 and 2023, respectively. The decrease in selling and administrative expenses of the DDS segment as a percentage of DDS segment revenues was primarily attributable to higher revenues, offset in part by higher selling and administrative expenses.

Selling and administrative expenses for the Synodex segment were $0.1 million and $0.2 million for the three months ended June 30, 2024 and 2023, respectively, a decrease of $0.1 million or 50%. The decrease in selling and administrative expenses was primarily attributable to lower labor costs of $0.1 million. Selling and administrative expenses for the Synodex segment as a percentage of Synodex segment revenues were 5% and 9% for the three months ended June 30, 2024 and 2023, respectively. The decrease in selling and administrative expenses of the Synodex segment as a percentage of Synodex segment revenues was primarily attributable to lower selling and administrative expenses, offset in part by lower revenues.

Selling and administrative expenses for the Agility segment were $2.7 million and $2.6 million for the three months ended June 30, 2024 and 2023, respectively, an increase of $0.1 million or 4%. The increase in selling and administrative expenses relates to incentive awards. Selling and administrative expenses for the Agility segment as a percentage of Agility segment revenues were 52% and 60% for the three months ended June 30, 2024 and 2023, respectively. The decrease in selling and administrative expenses of the Agility segment as a percentage of Agility segment revenues was primarily due to higher revenues, offset in part by higher selling and administrative expenses.

Income Taxes

We recorded a provision for income taxes of $0.3 million and $0.2 million for the three months ended June 30, 2024 and 2023, respectively.

Net Income (Loss)

We had a de minimis net loss during the three months ended June 30, 2024 and a net loss of $0.8 million during the three months ended June 30, 2023. The $0.8 million change was a result of higher revenues in the DDS and Agility segments and lower selling and administrative expenses and direct operating costs in the Synodex segment, offset in part by higher direct operating costs and selling and administrative expenses in the DDS and Agility segments, and a higher income tax provision.

Net loss for the DDS segment was $0.5 million and $0.6 million for the three months ended June 30, 2024 and 2023, respectively. The $0.1 million change was primarily attributable to higher revenues, offset in part by higher direct operating costs and selling and administrative expenses, and a higher income tax provision.

Net income for the Synodex segment was $0.3 million and $0.1 million for the three months ended June 30, 2024 and 2023, respectively. The $0.2 million increase was due to lower direct operating costs and selling and administrative expenses, offset in part by lower revenues in the current quarter.

Net income for the Agility segment was $0.1 million and a net loss of $0.3 million for the three months ended June 30, 2024 and 2023, respectively. The $0.4 million change was due to higher revenues offset by higher direct operating costs, and higher selling and administrative expenses in the current quarter.

Adjusted Gross Profit and Margin

Adjusted Gross Profit and Adjusted Gross Margin are non-GAAP financial measures. For a reconciliation of Adjusted Gross Profit and Adjusted Gross Margin to the most directly comparable GAAP measure, please see the description of “Non-GAAP Financial Measures – Adjusted Gross Profit and Adjusted Gross Margin” above.

Adjusted gross profit was $10.8 million and $8.1 million for the three months ended June 30, 2024 and 2023, respectively. The $2.7 million increase in adjusted gross profit was primarily due to higher revenues in the DDS and Agility segments and lower direct operating costs for the Synodex segment, offset in part by higher direct operating costs in the DDS and Agility segments. Adjusted gross margin was 33% and 41% for the three months ended June 30, 2024 and 2023, respectively. The decrease in adjusted gross margin was primarily due to higher revenues in the DDS and Agility segments and lower direct operating costs for the Synodex segment; offset in part by higher direct operating costs in the DDS and Agility segments.

Adjusted gross profit for the DDS segment was $6.6 million and $4.7 million for the three months ended June 30, 2024 and 2023, respectively. The $1.9 million increase in adjusted gross profit for the DDS segment was due to higher revenues, offset in part by higher direct operating costs. Adjusted gross margin for the DDS segment was 26% and 36% for the three months ended June 30, 2024 and 2023, respectively. The decrease in the adjusted gross margin for the DDS segment as a percentage of revenues was primarily due to higher revenues, offset in part by higher direct operating costs.

Adjusted gross profit for the Synodex segment was $0.6 million and $0.5 million for the three months ended June 30, 2024 and 2023, respectively. The $0.1 million increase in adjusted gross profit in the Synodex segment was due to lower direct operating costs, offset in part by lower revenues. Adjusted gross margin for the Synodex segment was 31% and 22% for the three months ended June 30, 2024 and 2023, respectively. The increase in the adjusted gross margin for the Synodex segment as a percentage of revenues was primarily due to lower direct operating costs, offset in part by lower revenues.

Adjusted gross profit for the Agility segment was $3.6 million and $3.0 million for the three months ended June 30, 2024 and 2023, respectively. The $0.6 million increase in adjusted gross profit for the Agility segment was due to higher revenues, offset in part by higher direct operating costs. Adjusted gross margin for the Agility segment was 70% and 68% for the three months ended June 30, 2024 and 2023, respectively. The increase in the adjusted gross margin for the Agility segment as a percentage of revenues was primarily due to higher revenues, offset in part by higher direct operating costs.

Adjusted EBITDA

Adjusted EBITDA is a non-GAAP financial measure. For a reconciliation of Adjusted EBITDA to the most directly comparable GAAP measure, please see the description of “Non-GAAP Financial Measures – Adjusted EBITDA” above.

Adjusted EBITDA was $2.8 million and $1.6 million for the three months ended June 30, 2024 and 2023, respectively. The $1.2 million increase in Adjusted EBITDA was due to the lower net loss in this quarter, a higher income tax provision, and higher depreciation and amortization.

Adjusted EBITDA for the DDS segment was $1.3 million and $0.8 million for the three months ended June 30, 2024 and 2023, respectively. The $0.5 million increase in Adjusted EBITDA in the DDS Segment was due to a higher income tax provision, higher depreciation and amortization and a lower net loss in this quarter.

Adjusted EBITDA for the Synodex segment was $0.5 million and $0.3 million for the three months ended June 30, 2024 and 2023, respectively. The $0.2 million increase in Adjusted EBITDA in the Synodex segment was due to higher net income in this quarter.

Adjusted EBITDA for the Agility segment was $1.0 million and $0.4 million for the three months ended June 30, 2024 and 2023, respectively. The $0.6 million increase in Adjusted EBITDA in the Agility segment was due to the net income in the current quarter compared to the net loss in the comparative quarter.

Six Months Ended June 30, 2024 and 2023

Revenues

Total revenues were $59.1 million and $38.5 million for the six months ended June 30, 2024 and 2023, respectively, an increase of $20.6 million or approximately 54%.

Revenues from the DDS segment were $45.1 million and $25.9 million for the six months ended June 30, 2024 and 2023, respectively, an increase of $19.2 million or approximately 74%. The increase was primarily attributable to higher volume from an existing customer.

Revenues from the Synodex segment were $3.9 million and $4.0 million for the six months ended June 30, 2024 and 2023, respectively, a decrease of $0.1 million or approximately 3%. The decrease was primarily attributable to lower volume from existing customers.

Revenues from the Agility segment were $10.1 million and $8.6 million for the six months ended June 30, 2024 and 2023, respectively, an increase of $1.5 million or approximately 17%. The increase was primarily attributable to higher volumes from subscriptions to our Agility AI-enabled industry platform.

One customer in the DDS segment generated approximately 31% of the Company’s total revenues for the six months ended June 30, 2024. Another two customers in the DDS segment generated approximately 10.7% and 10.6% of the Company’s total revenues for the six months ended June 30, 2023, respectively. No other customer accounted for 10% or more of total revenues during these periods. Further, revenues from non-U.S. customers accounted for 29% and 42% of the Company’s total revenues for the six months ended June 30, 2024 and 2023, respectively.

Direct Operating Costs

Direct operating costs consist of direct and indirect labor costs, occupancy costs, data center hosting fees, cloud services, content acquisition costs, depreciation and amortization, travel, telecommunications, computer services and supplies, realized (gain) loss on forward contracts, foreign currency revaluation (gain) loss, and other direct expenses that are incurred in providing services to our customers.

Direct operating costs were $40.1 million and $25.6 million for the six months ended June 30, 2024 and 2023, respectively, an increase of $14.5 million or 57%. The cost increase was primarily due to increased headcount to support higher volumes from an existing customer. The increase in direct operating costs includes a net increase of $10.8 million from direct and indirect labor related costs primarily on account of new hires and higher incentives; higher recruitment fees of $3.6 million; higher depreciation and amortization of capitalized developed software of $0.4 million; higher content costs of $0.4 million; higher subscription costs of $0.3 million; offset in part by a favorable impact of foreign exchange rate fluctuations of $1.0 million. Direct operating costs as a percentage of total revenues were 68% and 66% for the six months ended June 30, 2024 and 2023, respectively. The increase in direct operating cost as a percentage of total revenues was primarily due to higher revenues in the DDS and Agility segments and lower direct operating costs in the Synodex and Agility segments, offset in part by higher direct operating costs in the DDS segment.

Direct operating costs for the DDS segment were $32.5 million and $17.4 million for the six months ended June 30, 2024 and 2023, respectively, an increase of $15.1 million or 87%. The cost increase was primarily due to increased headcount to support higher volumes from an existing customer. The increase in direct operating costs includes a net increase of $11.9 million from direct and indirect labor related costs primarily on account of new hires and higher incentives; higher recruitment fees of $3.6 million; higher depreciation and amortization of capitalized developed software of $0.3 million; higher subscription costs of $0.2 million; offset in part by a favorable impact of foreign exchange rate fluctuations of $0.9 million. Direct operating costs for the DDS segment as a percentage of DDS segment revenues were 72% and 67% for the six months ended June 30, 2024 and 2023, respectively. The increase in direct operating costs of the DDS segment as a percentage of DDS segment revenues was primarily attributable to higher revenues, offset in part by higher direct operating costs.

Direct operating costs for the Synodex segment were $3.0 million and $3.5 million for the six months ended June 30, 2024 and 2023, respectively, a decrease of $0.5 million or 14%. The decrease in direct operating costs was primarily due to the effect of our cost optimization initiatives completed in 2023 which resulted in cost efficiencies for the Synodex segment. The reduction was primarily due to lower direct labor costs of $0.5 million. Direct operating costs for the Synodex segment as a percentage of Synodex segment revenues were 77% and 88% for the six months ended June 30, 2024 and 2023, respectively. The decrease in direct operating costs of the Synodex segment as a percentage of Synodex segment revenues was due to a decrease in direct operating costs, offset in part by lower revenues.

Direct operating costs for the Agility segment were $4.6 million and $4.7 million for the six months ended June 30, 2024 and 2023, respectively, a decrease of $0.1 million or 2%. The decrease in direct operating costs was primarily due to the effect of our cost optimization initiatives completed in 2023 which resulted in cost efficiencies for the Agility segment. The reduction was primarily due to lower direct labor costs of $0.6 million including severance and a favorable impact of foreign exchange rate fluctuations of $0.1 million; offset in part by higher content costs of $0.4 million and higher depreciation and amortization of capitalized developed software of $0.1 million and an increase in other direct operating costs of $0.1 million. Direct operating costs for the Agility segment as a percentage of Agility segment revenues were 46% and 55% for the six months ended June 30, 2024 and 2023, respectively. The decrease in direct operating costs of the Agility segment as a percentage of Agility segment revenues was due to higher revenues and lower direct operating costs.

Gross Profit and Gross Margin

Gross profit is derived by revenues less direct operating costs, while the Gross margin percentage is derived by dividing gross profit over revenues.

Gross profit was $19.0 million and $12.9 million for the six months ended June 30, 2024 and 2023, respectively. The $6.1 million increase in gross profit was primarily due to higher revenues in the DDS and Agility segments and lower direct operating costs for the Synodex and Agility segments, offset in part by higher direct operating costs in the DDS segment. Gross margin was 32% and 34% for the six months ended June 30, 2024 and 2023, respectively. The decrease in gross margin was primarily due to higher revenues in the DDS and Agility segments and lower direct operating costs for the Synodex and Agility segments, offset in part by higher direct operating costs in the DDS segment.

Gross profit for the DDS segment was $12.6 million and $8.6 million for the six months ended June 30, 2024 and 2023, respectively. The $4.0 million increase in gross profit for the DDS segment was primarily due to higher revenues, offset in part by higher direct operating costs. Gross margin for the DDS segment was 28% and 33% for the six months ended June 30, 2024 and 2023, respectively. The decrease in gross margin for the DDS segment as a percentage of revenues was primarily due to higher revenues offset in part by higher direct operating costs.

Gross profit for the Synodex segment was $0.9 million and $0.5 million for the six months ended June 30, 2024 and 2023, respectively. The $0.4 million increase in gross profit for the Synodex segment was primarily due to lower direct operating costs, offset in part by lower revenues. Gross margin for the Synodex segment was 22% and 13% for the six months ended June 30, 2024 and 2023, respectively. The increase in gross margin for the Synodex segment as a percentage of revenues was primarily due to lower direct operating costs, offset in part by lower revenues.

Gross profit for the Agility segment was $5.5 million and $3.9 million for the six months ended June 30, 2024 and 2023, respectively. The $1.6 million increase in gross profit for the Agility segment was primarily due to higher revenues and lower direct operating costs. Gross margin for the Agility segment was 54% and 45% for the six months ended June 30, 2024 and 2023, respectively. The increase in gross margin for the Agility segment as a percentage of revenues was primarily due to higher revenues and lower direct operating costs.

Selling and Administrative Expenses

Selling and administrative expenses consist of payroll and related costs including commissions, bonuses, and stock-based compensation; marketing, advertising, trade conferences and related expenses; new services research and related software development expenses, software subscriptions, professional and consultant fees, provision for credit losses and other administrative overhead expenses.

Selling and administrative expenses were $17.3 million and $15.4 million for the six months ended June 30, 2024 and 2023, respectively, an increase of $1.9 million or 12%. The increase in selling and administrative expenses was primarily due to higher expenses associated with the increase in revenues. The increase in selling and administrative expenses includes higher selling and administrative labor and related expenses of $1.0 million, primarily on account of new hires, salary increases, incentives and bonuses awarded; offset in part by lower severance; higher professional fees of $0.6 million; higher expenses for marketing related activities of $0.2 million; an unfavorable impact of foreign exchange rate fluctuations of $0.1 million; and an increase in other selling and administrative expenses of $0.2 million; offset in part by lower provisions for credit losses of $0.2 million. Selling and administrative expenses as a percentage of total revenues were 29% and 40% for the six months ended June 30, 2024 and 2023, respectively. The decrease in selling and administrative expenses as a percentage of total revenues was primarily attributable to higher revenues in the DDS and Agility segments and lower selling and administrative expenses in the Synodex and Agility segments, offset in part by higher selling and administrative expenses in the DDS segment.

Selling and administrative expenses for the DDS segment were $11.9 million and $9.3 million for the six months ended June 30, 2024 and 2023, respectively, an increase of $2.6 million or 28%. The increase in selling and administrative expenses was primarily due to higher expenses associated with the increase in revenues. The increase in selling and administrative expenses includes higher selling and administrative labor and related expenses of $1.5 million, primarily on account of new hires, salary increases, incentives and bonuses awarded; higher professional fees of $0.6 million; higher expenses for marketing related activities of $0.2 million and an increase in other selling and administrative expenses of $0.4 million; offset in part by lower provisions for credit losses of $0.1 million. Selling and administrative expenses for the DDS segment as a percentage of DDS segment revenues were 26% and 36% for the six months ended June 30, 2024 and 2023, respectively. The decrease in selling and administrative expenses of the DDS segment as a percentage of DDS segment revenues was primarily attributable to higher revenues, offset in part by higher selling and administrative expenses.

Selling and administrative expenses for the Synodex segment were $0.3 million and $0.4 million for the six months ended June 30, 2024 and 2023, respectively, a decrease of $0.1 million or 25%. The decrease in selling and administrative expenses was primarily attributable to lower selling and administrative labor costs of $0.1 million. Selling and administrative expenses for the Synodex segment as a percentage of Synodex segment revenues were 8% and 10% for the six months ended June 30, 2024 and 2023, respectively. The decrease in selling and administrative expenses of the Synodex segment as a percentage of Synodex segment revenues was primarily attributable to lower selling and administrative expenses.

Selling and administrative expenses for the Agility segment were $5.1 million and $5.7 million for the six months ended June 30, 2024 and 2023, respectively, a decrease of $0.6 million or 11%. The decrease in selling and administrative expenses was primarily due to the effect of our cost optimization initiatives completed in 2023 which resulted in cost efficiencies for the Agility segment. The decrease in selling and administrative expenses includes lower selling and administrative labor and related expenses of $0.4 million, primarily on account of headcount reduction and severance; lower provision for credit losses of $0.1 million; and a decrease in other selling and administrative expenses of $0.2 million; offset in part by an unfavorable impact of foreign exchange rate fluctuations of $0.1 million. Selling and administrative expenses for the Agility segment as a percentage of Agility segment revenues were 50% and 66% for the six months ended June 30, 2024 and 2023, respectively. The decrease in selling and administrative expenses of the Agility segment as a percentage of Agility segment revenues was primarily due to higher revenues and lower selling and administrative expenses.

Income Taxes

We recorded a provision for income taxes of $0.7 million and $0.4 million for the six months ended June 30, 2024 and 2023, respectively.

Income taxes primarily consist of a provision for foreign taxes recorded by the Company’s foreign subsidiaries in accordance with local tax regulations. The estimated annual effective tax rate applied to the six-month period ended June 30, 2024, differs from the U.S. federal statutory rate of 21% principally due to income earned outside the United States which is subject to the U.S. tax on global intangible low taxed income (“GILTI”), tax effects of foreign operations, changes in valuation allowance, provision on uncertain tax positions, and other net increases; offset in part by a reduction in foreign exchange gains and losses, deemed interest and true up adjustment on prior year tax provision.

Net Income (Loss)

We had a net income of $1.0 million and a net loss of $2.9 million during the six months ended June 30, 2024 and 2023, respectively. The $3.9 million change was a result of higher revenues in the DDS and Agility segments and lower selling and administrative expenses and direct operating costs in the Synodex and Agility segments and interest income of $0.1 million from the refund of a court fee deposit for our Indian subsidiary’s service tax case; offset in part by higher direct operating costs and selling and administrative expenses in the DDS segment, and a higher income tax provision.

The DDS segment was at breakeven and a net loss of $1.2 million for the six months ended June 30, 2024 and 2023, respectively. The $1.2 million change was primarily attributable to higher revenues, and interest income of $0.1 million from the refund of a court fee deposit for our Indian subsidiary’s service tax case in the period; offset in part by higher direct operating costs and selling and administrative expenses, and a higher income tax provision.

Net income for the Synodex segment was $0.6 million and $0.1 million for the six months ended June 30, 2024 and 2023, respectively. The $0.5 million increase was due to lower direct operating costs and selling and administrative expenses in the period.

Net income for the Agility segment was $0.4 million and a net loss of $1.8 million for the six months ended June 30, 2024 and 2023. The $2.2 million change was due to higher revenues, lower selling and administrative costs, and lower direct operating costs in the period.

Adjusted Gross Profit and Margin

Adjusted Gross Profit and Adjusted Gross Margin are non-GAAP financial measures. For a reconciliation of Adjusted Gross Profit and Adjusted Gross Margin to the most directly comparable GAAP measure, please see the description of “Non-GAAP Financial Measures – Adjusted Gross Profit and Adjusted Gross Margin” above.

Adjusted gross profit was $21.8 million and $15.5 million for the six months ended June 30, 2024 and 2023, respectively. The $6.3 million increase in adjusted gross profit was primarily due to higher revenues in the DDS and Agility segments and lower direct operating costs for the Synodex and Agility segments, offset in part by higher direct operating costs in the DDS segment. Adjusted gross margin was 37% and 40% for the six months ended June 30, 2024 and 2023, respectively. The decrease in adjusted gross margin was primarily due to higher revenues in the DDS and Agility segments and lower direct operating costs for the Synodex and Agility segments, offset in part by higher direct operating costs in the DDS segment.

Adjusted gross profit for the DDS segment was $13.6 million and $9.1 million for the six months ended June 30, 2024 and 2023, respectively. The $4.5 million increase in adjusted gross profit for the DDS segment was due to higher revenues, offset in part by higher direct operating costs. Adjusted gross margin for the DDS segment was 30% and 35% for the six months ended June 30, 2024 and 2023, respectively. The decrease in the adjusted gross margin for the DDS segment as a percentage of revenues was primarily due to higher revenues, offset in part by higher direct operating costs.

Adjusted gross profit for the Synodex segment was $1.1 million and $0.8 million for the six months ended June 30, 2024 and 2023, respectively. The $0.3 million increase in adjusted gross profit in the Synodex segment was due to lower direct operating costs, offset in part by lower revenues. Adjusted gross margin for the Synodex segment was 30% and 21% for the six months ended June 30, 2024 and 2023, respectively. The increase in the adjusted gross margin for the Synodex segment as a percentage of revenues was primarily due to lower direct operating costs, offset in part by lower revenues.

Adjusted gross profit for the Agility segment was $7.1 million and $5.6 million for the six months ended June 30, 2024 and 2023, respectively. The $1.5 million increase in adjusted gross profit for the Agility segment was due to higher revenues and lower direct operating costs. Adjusted gross margin for the Agility segment was 70% and 65% for the six months ended June 30, 2024 and 2023, respectively. The increase in the adjusted gross margin for the Agility segment as a percentage of revenues was primarily due to higher revenues and lower direct operating costs.

Adjusted EBITDA

Adjusted EBITDA is a non-GAAP financial measure. For a reconciliation of Adjusted EBITDA to the most directly comparable GAAP measure, please see the description of “Non-GAAP Financial Measures – Adjusted EBITDA” above.

Adjusted EBITDA was $6.6 million and $2.4 million for the six months ended June 30, 2024 and 2023, respectively. The $4.2 million increase in Adjusted EBITDA was due to the net income in the current period compared to the net loss in the comparative period, a higher income tax provision, higher depreciation and amortization and stock-based compensation, offset in part by lower non-recurring severance.

Adjusted EBITDA for the DDS segment was $3.5 million and $1.5 million for the six months ended June 30, 2024 and 2023, respectively. The $2.0 million increase in Adjusted EBITDA in the DDS Segment was due to lower net loss in the period, a higher income tax provision, higher depreciation and amortization, and stock-based compensation.

Adjusted EBITDA for the Synodex segment was $1.0 million and $0.6 million for the six months ended June 30, 2024 and 2023, respectively. The $0.4 million increase in Adjusted EBITDA in the Synodex segment was due to higher net income for the period.

Adjusted EBITDA for the Agility segment was $2.1 million and $0.3 million for the six months ended June 30, 2024 and 2023, respectively. The $1.8 million change in Adjusted EBITDA in the Agility segment was due to the net income in the current period compared to the net loss in the comparative period, higher depreciation and amortization, offset in part by lower non-recurring severance.

Liquidity and Capital Resources

Selected measures of liquidity and capital resources, expressed in thousands, were as follows:

​ ​ ​ ​ ​ ​ ​ June 30, 2024 ​ ​ ​ ​ December 31, 2023
Cash and cash equivalents ​ $16,509 ​ $13,806
Short term investments - other ​ ​ 14 ​ ​ 14
Working capital ​ 11,963 ​ 9,142

On June 30, 2024, we had cash and cash equivalents of $16.5 million, of which $6.6 million was held by our foreign subsidiaries, and $9.9 million was held in the United States. Despite the passage of the new tax law under which we may repatriate funds from overseas after paying the toll charge, it is our intent, as of June 30, 2024, to indefinitely reinvest the overseas funds in our foreign subsidiaries due to the withholding tax that we would have to incur on the actual remittances.

We have used, and plan to use, our cash and cash equivalents for (i) capital investments; (ii) the expansion of our operations; (iii) technology innovation; (iv) product management and strategic marketing; (v) general corporate purposes, including working capital; and (vi) possible business acquisitions. As of June 30, 2024, we had working capital of approximately $12.0 million, as compared to working capital of approximately $9.1 million as of December 31, 2023. The increase in working capital is due to increased collections from higher revenues and proceeds from stock option exercises in the period.

We did not have any material commitments for capital expenditures as of June 30, 2024.

We believe that our existing cash and cash equivalents and internally generated funds will provide sufficient sources of liquidity to satisfy our financial needs for at least the next 12 months from the date of this Report.

On April 4, 2023, we entered into a Credit Agreement (the “Credit Agreement”) with Wells Fargo Bank, National Association, as lender, and Innodata Inc., Innodata Synodex, LLC, Innodata docGenix, LLC and Agility PR Solutions LLC as co-borrowers. On July 21, 2023, Innodata Services LLC signed a Joinder Agreement to join the Credit Agreement as a co-borrower. The Credit Agreement provides for a secured revolving line of credit (the “Revolving Credit Facility”) up to an amount equal to the lesser of the borrowing base and $10.0 million with a maturity date of April 4, 2026. The Revolving Credit Facility’s borrowing base is calculated in accordance with the terms of the Credit Agreement and on the basis of 85% of eligible accounts, 85% of eligible foreign accounts up to $2.0 million and certain other reserves and adjustments. As of June 30, 2024, such borrowing base calculation equaled approximately $10.0 million. The Credit Agreement contains a financial covenant that requires the Borrowers, on a consolidated basis, to maintain a fixed charge coverage ratio of not less than 1.10 to 1.00 by December 31, 2024. Except as set forth in the Credit Agreement, borrowings under the Revolving Credit Facility bear interest at a rate equal to the daily simple secured overnight financing rate (“SOFR”) plus 2.25%. We did not utilize the Revolving Credit Facility during the six months ended June 30, 2024 and through the date of filing of this Report.

Cash Flows

Net Cash Provided by Operating Activities

Cash provided by our operating activities for the six months ended June 30, 2024 was $6.3 million resulting from net income of $1.0 million, adjusted for non-cash expenses of $5.1 million and an increase in working capital of $0.2 million. Refer to the Condensed Consolidated Statements of Cash Flows for further details.

Cash provided by our operating activities for the six months ended June 30, 2023 was $4.2 million resulting from our net loss of $2.9 million, adjusted for non-cash expenses of $4.6 million and an increase in working capital of $2.5 million. Refer to the Condensed Consolidated Statements of Cash Flows for further details.

Net Cash Used in Investing Activities

For the six months ended June 30, 2024 and 2023, cash used in our investing activities was $4.1 million and $2.5 million, respectively. These capital expenditures were principally for the purchase of technology equipment including servers, network infrastructure and workstations, and expenditures for capitalized developed software. Capital expenditures for the six months ended June 30, 2024 amounting to $4.1 million consisted of $2.5 million for the DDS segment, $1.0 million for the Agility segment and $0.6 million for the Synodex segment.

During the next 12 months, it is anticipated that capital expenditures for capitalized developed software and ongoing technology, equipment and infrastructure upgrades will approximate to $6.0 million, a portion of which we may finance.

Net Cash Provided by (Used in) Financing Activities

Cash provided by financing activities for the six months ended June 30, 2023 was $0.4 million primarily from proceeds of stock option exercises of $0.8 million, offset in part by payment of long-term obligations of $0.3 million and withholding taxes on net settlement of restricted stock awards of $0.1 million.

Cash provided by financing activities for the six months ended June 30, 2023 was $2.0 million primarily from proceeds of stock option exercises of $2.2 million, offset in part by payment of long-term obligations of $0.2 million.

Critical Accounting Policies and Estimates

Our discussion and analysis of our results of operations, liquidity and capital resources is based on our condensed consolidated financial statements, which have been prepared in conformity with U.S. GAAP. The preparation of the condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates and judgments, including those related to revenue recognition, allowance for credit losses and billing adjustments, long-lived assets, intangible assets, goodwill, valuation of deferred tax assets, value of securities underlying stock-based compensation, litigation accruals, pension benefits, valuation of derivative instruments and estimated accruals for various tax exposures. We base our estimates on historical and anticipated results and trends and on various other assumptions that we believe are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. By their nature, estimates are subject to an inherent degree of uncertainty. Actual results may differ from our estimates and could have a significant adverse effect on our condensed consolidated results of operations and financial position.

The significant accounting policies used in preparing our condensed consolidated financial statements contained in this Report are the same as those described in the Company’s Annual Report on Form 10-K, unless otherwise noted, and we believe those critical accounting policies affect our more significant estimates and judgments in the preparation of our condensed consolidated financial statements.

Off-Balance Sheet Arrangements

None.

Controls and procedures

As filed, 1,486 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We maintain disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (Exchange Act), that are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Under the supervision, and with the participation of our management, including our principal executive officer and our principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures, as defined under Exchange Act Rule 13a-15(e), as of June 30, 2024. Based on this evaluation, our principal executive officer and our principal financial officer concluded that, as of June 30, 2024, our disclosure controls and procedures were effective.

There have been no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) or 15d-15(f) under the Exchange Act) during the six months ended June 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 159 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

For information regarding Risk Factors, please refer to Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2024-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Selling, general and administrative3 months2024-04-01 to 2024-06-30$9.0mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2024-01-01 to 2024-06-30$17.3mus-gaap:SellingGeneralAndAdministrativeExpense
Income tax3 months2024-04-01 to 2024-06-30$285.0kus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2024-01-01 to 2024-06-30$709.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2024-04-01 to 2024-06-30−$14.0kus-gaap:NetIncomeLoss
Diluted EPS3 months2024-04-01 to 2024-06-30$0.00us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2024-01-01 to 2024-06-30$0.03us-gaap:EarningsPerShareDiluted
Basic EPS3 months2024-04-01 to 2024-06-30$0.00us-gaap:EarningsPerShareBasic
Basic EPS6 months2024-01-01 to 2024-06-30$0.03us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2024-04-01 to 2024-06-3028,878,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2024-01-01 to 2024-06-3032,691,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2024-01-01 to 2024-06-30$6.3mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2024-01-01 to 2024-06-30$4.1mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2024-06-30$16.5mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2024-06-30$38.3mus-gaap:AssetsCurrent
Total assetsAt period end2024-06-30$66.0mus-gaap:Assets
Current liabilitiesAt period end2024-06-30$26.4mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2024-06-30$37.7mus-gaap:Liabilities
Shareholders' equityAt period end2024-06-30$29.0mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001410578-24-001246. Last ingested by Listed: Nov 6, 2026, 18:30 ET. Listed shows no prices and gives no investment advice.